XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.22.4

Share-Based Compensation | 12 Months Ended
--- | ---
Jan. 01, 2023
Share-Based Payment Arrangement [Abstract] |
Share-Based Compensation | Share-Based CompensationThe Company has the ability to grant stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and performance compensation awards to current or prospective employees, directors, officers, consultants or advisors. During 2020, the Company’s Board of Directors and its stockholders approved the adoption of the 2020 Omnibus Award Plan (the “2020 Plan”) for the issuance of equity instruments as described above. The Company’s previous 2010 Omnibus Award Plan (as amended, the “2010 Plan”) expired in accordance with its terms in 2020. All equity grants in 2022 and 2021 were issued from the 2020 Plan. Equity grants in 2020 were issued from both the 2020 Plan and the 2010 Plan. The 2020 Plan is currently the only equity plan from which future equity awards may be granted, but outstanding awards granted under the 2010 Plan will continue to be governed by the terms of the 2010 Plan. As of January 1, 2023, there were approximately 18,168 shares of common stock available for future grants under the 2020 Plan. During the periods presented in the consolidated financial statements, the Company settled all exercises of stock options and vesting of restricted shares, including performance shares, with treasury shares. Stock Options The Company’s current outstanding stock options have maximum contractual terms of 10 years and vest ratably over three years or cliff vest after three years. The exercise price of options granted is equal to the market price of the Company’s common stock on the date of grant. The fair value of stock options on the date of grant is calculated using the Black-Scholes Model. The aggregate intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. The following table summarizes stock option activity during 2022:
| Number of Options |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life in Years |  | Aggregate Intrinsic Value
Outstanding at January 2, 2022 | 9,858 |  |  | $ | 18.44 |  |  |  |  |
Granted | 1,562 |  |  | 21.40 |  |  |  |  |
Exercised | (414) |  |  | 13.82 |  |  |  |  |
Forfeited and/or expired | (116) |  |  | 21.93 |  |  |  |  |
Outstanding at January 1, 2023 | 10,890 |  |  | $ | 19.00 |  |  | 6.60 |  | $ | 41,181 |
Vested or expected to vest at January 1, 2023 | 10,770 |  |  | $ | 18.97 |  |  | 6.57 |  | $ | 41,084 |
Exercisable at January 1, 2023 | 7,844 |  |  | $ | 17.73 |  |  | 5.69 |  | $ | 39,116 |
The total intrinsic value of options exercised during 2022, 2021 and 2020 was $2,979, $39,522 and $28,111, respectively. The weighted average grant date fair value of stock options granted during 2022, 2021 and 2020 was $6.33, $6.33 and $6.02, respectively. The weighted average grant date fair value of stock options was determined using the following assumptions:
| 2022 |  | 2021 |  | 2020
Risk-free interest rate | 3.00 | % |  | 0.70 | % |  | 0.22 | %
Expected option life in years | 4.75 |  | 4.50 |  | 4.50
Expected volatility | 37.82 | % |  | 38.00 | % |  | 38.02 | %
Expected dividend yield | 2.34 | % |  | 2.03 | % |  | 1.72 | %
The risk-free interest rate represents the U.S. Treasury zero-coupon bond yield correlating to the expected life of the stock options granted. The expected option life represents the period of time that the stock options granted are expected to be outstanding based on historical exercise trends for similar grants. The expected volatility is based on the historical market price volatility of the Company over a period equivalent to the expected option life. The expected dividend yield represents the Company’s annualized average yield for regular quarterly dividends declared prior to the respective stock option grant dates. The Black-Scholes Model has limitations on its effectiveness including that it was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable and that the model requires the use of highly subjective assumptions, such as expected stock price volatility. Employee stock option awards have characteristics significantly different from those of traded options and changes in the subjective input assumptions can materially affect the fair value estimates. Restricted Shares The Company grants RSAs and RSUs, which primarily cliff vest after one to three years, respectively. For the purposes of our disclosures, the term “Restricted Shares” applies to RSAs and RSUs collectively unless otherwise noted. The fair value of Restricted Shares granted is determined using the fair market value of the Company’s common stock on the date of grant, as set forth in the applicable plan document. The following table summarizes activity of Restricted Shares during 2022:
| Number of Restricted Shares |  | Weighted Average Grant Date Fair Value
Non-vested at January 2, 2022 | 1,094 |  |  | $ | 20.09 |
Granted | 429 |  |  | 20.34 |
Vested | (279) |  |  | 20.38 |
Forfeited | (58) |  |  | 21.65 |
Non-vested at January 1, 2023 | 1,186 |  |  | $ | 20.03 |
The total fair value of Restricted Shares that vested in 2022, 2021 and 2020 was $5,564, $7,048 and $8,634, respectively. Performance Shares The Company grants performance-based awards to certain officers and key employees. The vesting of these awards is contingent upon meeting one or more defined operational or financial goals (a performance condition) or common stock share prices (a market condition). The quantity of shares awarded ranges from 0% to 200% of “Target,” as defined in the award agreement as the midpoint number of shares, based on the level of achievement of the performance and market conditions. The fair values of the performance condition awards granted in 2022, 2021 and 2020 were determined using the fair market value of the Company’s common stock on the date of grant, as set forth in the applicable plan document. Share-based compensation expense recorded for performance condition awards is reevaluated at each reporting period based on the probability of the achievement of the goal. The fair value of market condition awards granted in 2022, 2021 and 2020 were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that the market conditions will be achieved and is applied to the trading price of our common stock on the date of grant. The input variables are noted in the table below:
| 2022 |  | 2021 |  | 2020
Risk-free interest rate | 1.71 | % |  | 0.20 | % |  | 1.38 | %
Expected life in years | 3.00 |  | 3.00 |  | 3.00
Expected volatility | 52.33 | % |  | 49.47 | % |  | 23.26 | %
Expected dividend yield (a) | 0.00 | % |  | 0.00 | % |  | 0.00 | %
_______________ (a)The Monte Carlo method assumes a reinvestment of dividends. Share-based compensation expense is recorded ratably for market condition awards during the requisite service period and is not reversed, except for forfeitures, at the vesting date regardless of whether the market condition is met. The following table summarizes activity of performance shares at Target during 2022:
| Performance Condition Awards |  | Market Condition Awards
| Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value
Non-vested at January 2, 2022 | 505 |  |  | $ | 20.48 |  |  | 422 |  |  | $ | 24.52 |
Granted | 207 |  |  | 21.94 |  |  | 148 |  |  | 30.70 |
Dividend equivalent units issued (a) | 14 |  |  | 21.67 |  |  | 11 |  |  | 27.37 |
Vested | (75) |  |  | 17.86 |  |  | (99) |  |  | 21.37 |
Forfeited | (67) |  |  | 17.86 |  |  | (20) |  |  | 21.38 |
Non-vested at January 1, 2023 | 584 |  |  | $ | 21.67 |  |  | 462 |  |  | $ | 27.38 |
_______________ (a)Dividend equivalent units are issued in lieu of cash dividends for non-vested performance shares. There is no weighted average fair value associated with dividend equivalent units. The total fair value of performance condition awards that vested in 2022, 2021 and 2020 was $1,712, $1,784 and $3,447, respectively. The total fair value of market condition awards that vested in 2022, 2021 and 2020 was $2,253, $3,498 and $4,910, respectively. Share-Based Compensation Total share-based compensation and the related income tax benefit recognized in the Company’s consolidated statements of operations were as follows:
| Year Ended
| 2022 |  | 2021 |  | 2020
Stock options | $ | 9,072 |  |  | $ | 9,256 |  |  | $ | 8,499 |
Restricted shares (a) | 7,106 |  |  | 6,677 |  |  | 6,507 |
Performance shares: |  |  |  |  |
Performance condition awards | 4,431 |  |  | 2,861 |  |  | 782 |
Market condition awards | 3,929 |  |  | 3,225 |  |  | 2,521 |
Modifications, net | — |  |  | — |  |  | 621 |
Share-based compensation | 24,538 |  |  | 22,019 |  |  | 18,930 |
Less: Income tax benefit | (3,043) |  |  | (2,790) |  |  | (2,958) |
Share-based compensation, net of income tax benefit | $ | 21,495 |  |  | $ | 19,229 |  |  | $ | 15,972 |
_______________ (a)2021 and 2020 include $19 and $213, respectively, related to retention awards in connection with the Company’s G&A Realignment Plan, which is included in “Reorganization and realignment costs.” See Note 5 for further information. As of January 1, 2023, there was $30,038 of total unrecognized share-based compensation, which will be recognized over a weighted average amortization period of 1.98 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration